Literature DB >> 22689289

The role of CXCR3 and CXCR4 in colorectal cancer metastasis.

Teppei Murakami1, Kenji Kawada, Masayoshi Iwamoto, Masatoshi Akagami, Koya Hida, Yuki Nakanishi, Keitaro Kanda, Mayumi Kawada, Hiroshi Seno, Makoto Mark Taketo, Yoshiharu Sakai.   

Abstract

Chemokines and their receptors play key roles in leukocyte trafficking and are also implicated in cancer metastasis. We previously demonstrated that forced expression of CXCR3 promotes colon cancer metastasis preferentially to the draining lymph nodes (LNs), with poor prognosis. Using clinical colorectal cancer (CRC) samples, here, we show that expressions of CXCR3 and CXCR4 are significantly higher in metastatic foci within LNs and liver compared to primary tumors, whereas ligands for CXCR3 and CXCR4 are not. We also have demonstrated that some human CRC cell lines constitutively express both CXCR3 and CXCR4, and that activation of CXCR3 strengthens the CXCR4-mediated cell migration in vitro in a synergistic manner. By constructing SW620 cell lines with reduced expression of CXCR3 and/or CXCR4 using microRNA, we investigated in vivo metastatic activities in a mouse rectal transplantation model. Six weeks after inoculation, CXCR3-, CXCR4-, and CXCR3/CXCR4 double-knockdowns significantly reduced metastasis to LNs, liver and lungs, compared to the control (p < 0.05). Importantly, its suppressive effect on LN metastasis was significantly stronger in CXCR3- and CXCR3/CXCR4 double-knockdowns. In addition, CXCR3- and CXCR3/CXCR4 double-knockdowns significantly decreased the dissemination of cancer cells to liver and lungs, even after 2 weeks. These results indicate that targeting CXCR3 and CXCR4 can be a promising therapy against CRC metastasis.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689289     DOI: 10.1002/ijc.27670

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  57 in total

Review 1.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.

Authors:  Xiaoqin Lan; Fang Xiao; Qiang Ding; Jiqiao Liu; Jingmei Liu; Junhua Li; Jiong Zhang; De-An Tian
Journal:  J Mol Histol       Date:  2014-08-24       Impact factor: 2.611

Review 3.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

4.  A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis.

Authors:  Z Xiang; Z-J Zhou; G-K Xia; X-H Zhang; Z-W Wei; J-T Zhu; J Yu; W Chen; Y He; R E Schwarz; R A Brekken; N Awasthi; C-H Zhang
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

Review 5.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

6.  Expression of chemokine receptor CXCR7 in colorectal carcinoma and its prognostic significance.

Authors:  Dan Yang; Tingting Dai; Lijun Xue; Xiaobei Liu; Bo Wu; Jian Geng; Xiaobei Mao; Rui Wang; Longbang Chen; Xiaoyuan Chu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 7.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

8.  Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach.

Authors:  Masaichi Ogawa; Michiaki Watanabe; Takuo Hasegawa; Kohei Ichihara; Kazuhiko Yoshida; Katsuhiko Yanaga
Journal:  Mol Clin Oncol       Date:  2017-04-04

Review 9.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

10.  PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.

Authors:  Nisha Nagarsheth; Dongjun Peng; Ilona Kryczek; Ke Wu; Wei Li; Ende Zhao; Lili Zhao; Shuang Wei; Timothy Frankel; Linda Vatan; Wojciech Szeliga; Yali Dou; Scott Owens; Victor Marquez; Kaixiong Tao; Emina Huang; Guobin Wang; Weiping Zou
Journal:  Cancer Res       Date:  2015-11-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.